Business Wire

GN-HEARING

18.8.2020 09:02:06 CEST | Business Wire | Press release

Share
ReSound ONE: an entirely new class of hearing aids that offers a truly individualized hearing experience and the best sound quality for every user

GN Hearing, the global leader in hearing aid innovation, today unveils ReSound ONETM , a revolutionary new hearing aid* that solves one of the most enduring challenges for people with hearing loss. This unique solution places an additional microphone inside the ear canal, for the first time, allowing people relying on hearing aids to experience the world with their own ears while preserving the comfort of an open-fit device. Now every user can enjoy the benefits of superior sound quality and hear conversations better in noisy environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200818005077/en/

With its Organic Hearing philosophy, GN has always taken its design inspiration from how humans hear naturally and seeks to mimic this within its technology as closely as possible. Following this approach, ReSound ONE uniquely adapts to the needs and lifestyle of every individual rather than the other way around.

The outer ear (pinna) is designed by nature to work like an acoustic antenna. It helps the brain localize and tune in to a particular sound, for example when listening to a specific voice in a crowded café. However, the most popular styles of hearing aids (Receiver-In-Ear and Behind-The-Ear models) capture sound from microphones that sit behind the ear and then approximate the effect of the pinna. The result is an averaged and incomplete reproduction of sound, making it hard for the brain to achieve its natural localization and noise-cancelling function. In fact, of the 79 million people who wear hearing aids globally,1 93% report having trouble hearing in noisy environments and 55% get confused about where sounds come from.2

ReSound ONE is the world’s first full-featured* hearing aid with a Microphone & Receiver-In-Ear design (M&RIE) that uses the unique shape of every individual’s ear to collect sound. This remarkable innovation has been achieved with a radical new receiver system combined with all-new Digital Feedback Suppression (DFS Ultra III), enabled by GN’s new and most powerful sound-processing chipset ever. By picking up sound directly inside the ear, ReSound ONE gives the brain everything it needs to tune in to individual voices, as well as significantly reducing background noise. Clinical studies show that all hearing aid users benefit from listening to sounds collected with their own ears, with 90% of users preferring the sound quality of ReSound ONE with M&RIE instead of only the microphone behind the ear.3,4

GN Hearing CEO and President, Gitte Aabo explains, “I am very proud that, once again, GN is first in the industry with ground-breaking innovation that will make a genuine difference in how people experience conversations and sounds around them. Placing a microphone into the ear with an open-fit hearing aid is something the industry has battled for many years to achieve. This technology will allow people with hearing loss to feel that they are literally getting their own hearing back and hearing the way nature intended. ReSound ONE will boost the communication, relationships, and confidence of every individual.”

Additionally, ReSound ONE incorporates new All Access Directionality and the user-activated Ultra Focus settings. These enhanced operating modes significantly improve speech recognition while preserving spatial perception in complex sound and noise situations. ReSound ONE includes unmatched rechargeability and extensive connectivity options to both iOS and Android™ smartphones for streaming and hearing aid control.

ReSound ONE is available from August 27, 2020 in rechargeable and non-rechargeable models. This technology is also available in new Beltone Imagine hearing aids.

For further information, visit the ReSound Newsroom and read more about the Organic Hearing philosophy.

Learn more about GN’s 2020 and beyond strategy with focus on individualized customer experiences.

- ENDS –

NOTES TO EDITORS

About ReSound

ReSound hearing aids, available from leading hearing care professionals, continue to set worldwide standards for quality and intuitive technology to help people with hearing loss communicate better than ever before. ReSound was the first hearing aid brand to be Made for iPhone, bringing direct streaming from hearing aids into the iPhone era. It also pioneered the development of 2.4 GHz wireless technology and made it possible to receive advanced at-home hearing care during COVID-19. The introduction of this new class of hearing technology with ReSound ONE demonstrates that ReSound is the undisputed innovation leader putting people with hearing loss at the center. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.

About GN Group

The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.

150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).

​​Visit our homepage GN.com, get to know our innovation and leadership​ ​​, and connect with us on LinkedIn , Facebook and Twitter .

*ReSound ONE introduces the world’s first full-featured hearing aid with M&RIE for a truly individualized, more complete sound experience. Full-featured means a microphone in the ear and two additional, standard directional microphones, directionality features and wireless audio streaming.

© 2020 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.

References

  1. World Health Organization (2020) Deafness and hearing loss. Factsheet. https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss . Accessed: July, 2020
  2. MarkeTrak 2019
  3. Jespersen et al (2020): M&RIE receiver preferred for sound quality and localization. ReSound white paper
  4. Groth J. (2020). An innovative RIE with microphone in the ear lets users “hear with their own ears”. ReSound white paper

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye